Delta-Fly Pharma (TSE:4598) Research & Development: 円1,329.68 Mil (TTM As of Mar. 2026)


TSE:4598 Delta-Fly Pharma Inc TSE:4598
30 GF Score
Price 円135.00
! 2 Warning Signs
View Full Analysis

What is Delta-Fly Pharma Research & Development?

Delta-Fly Pharma TSE:4598 +2.27% 30 Research & Development is 円1,329.68 Mil as of Mar. 2026. GuruFocus rates TSE:4598 with a GF Score™ of 30/100. The stock has 2 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Delta-Fly Pharma's Research & Development for the six months ended in Mar. 2026 was 円631.97 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was 円1,329.68 Mil.

Delta-Fly Pharma  (TSE:4598) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Delta-Fly Pharma Research & Development Related Terms

Delta-Fly Pharma Research & Development Historical Data

* Premium members only.

The historical data trend for Delta-Fly Pharma's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Delta-Fly Pharma Research & Development Chart

Delta-Fly Pharma Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 940.79 1,011.83 1,118.62 1,437.96 1,329.68

Delta-Fly Pharma Semi-Annual Data
Mar17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 662.42 782.90 655.06 697.71 631.97
TSE:4598
30GF Score
Delta-Fly Pharma Inc TSE:4598
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Delta-Fly Pharma Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was 円1,329.68 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of 円1,329.68 Mil mean?
Delta-Fly Pharma (TSE:4598) has a Research & Development of 円1,329.68 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Delta-Fly Pharma and its competitors.
Is Delta-Fly Pharma's Research & Development too high?
Delta-Fly Pharma's current Research & Development is 円1,329.68 Mil. Overall, Delta-Fly Pharma has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Delta-Fly Pharma's Research & Development compare to VRTX and REGN?
Delta-Fly Pharma's Research & Development of 円1,329.68 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Delta-Fly Pharma and its competitors. Delta-Fly Pharma's current Research & Development is 円1,329.68 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Delta-Fly Pharma stock overvalued right now?
Delta-Fly Pharma (TSE:4598) has a current Research & Development of 円1,329.68 Mil. The current Research & Development is 円1,329.68 Mil. Delta-Fly Pharma's overall GF Score™ is 30/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Delta-Fly Pharma (TSE:4598), the current Research & Development is 円1,329.68 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Delta-Fly Pharma Business Description

Address 37-5, Miyajima Nishikino, Kawauchi-cho, Tokushima, JPN, 771-0116
Delta-Fly Pharma Inc is a Japan-based company mainly engaged in the discovery and development of gentle anti-cancer agents with module technology.
30GF Score

Get the complete analysis for TSE:4598

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円135.00
Price